Inclusion Criteria

DISEASE CHARACTERISTICS: Histologically or cytologically confirmed metastatic small cell
lung cancer (SCLC) Must have sensitive or refractory disease after first-line chemotherapy
Refractory Progressive or stable disease during chemotherapy Relapse after a response
during treatment Relapse after a response within 3 months after completing chemotherapy
Sensitive Relapse after a response of at least 3 months duration after completing
chemotherapy At least 1 measurable lesion No previously irradiated lesions No symptomatic
brain or leptomeningeal metastasis

PATIENT CHARACTERISTICS: Age: 18 and over Performance status: WHO 0-1 Life expectancy: Not
specified Hematopoietic: Hemoglobin at least 9 g/dL Neutrophil count at least 1,500/mm3
Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 times upper
limit of normal (ULN) Alkaline phosphatase no greater than 2.5 times ULN ALT or AST no
greater than 2.5 times ULN Albumin at least 2.5 g/dL Renal: Creatinine no greater than 1.5
mg/dL OR Creatinine clearance at least 40 mL/min (60 mL/min if treated with prior
cisplatin therapy) Cardiovascular: No congestive heart failure or angina pectoris (even if
medically controlled) No myocardial infarction within the past year No uncontrolled
hypertension or arrhythmia Other: No other serious illness or medical condition No history
of significant neurologic disorder (other than metastatic disease or psychiatric disorder)
No uncontrolled infection No other malignancy within the past 5 years except curatively
treated nonmelanoma skin cancer, carcinoma in situ or the cervix, or other surgically
cured cancer No other condition that would preclude study Not pregnant or nursing Negative
pregnancy test Fertile patients must use effective contraception during and for at least 6
months after study

PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior immunotherapy for
SCLC and recovered No concurrent immunotherapy Chemotherapy: See Disease Characteristics
At least 4 weeks since prior chemotherapy (6 weeks for carboplatin at doses of at least
500 mg/m2 or AUC more than 7 mg/mL) and recovered No more than 1 prior chemotherapy
regimen No concurrent chemotherapy Endocrine therapy: At least 4 weeks since prior
hormonal therapy for SCLC and recovered No concurrent steroids for brain metastasis No
concurrent hormonal therapy Radiotherapy: See Disease Characteristics At least 2 weeks
since prior radiotherapy and recovered No concurrent radiotherapy except palliative local
radiotherapy for non-target lesions Surgery: At least 4 weeks since prior major surgery
and recovered Other: At least 30 days since prior investigational drugs and recovered No
other concurrent anti-cancer therapy No other concurrent investigational drugs